Alzheimer's disease and treatment of vascular risk factors;De ziekte van Alzheimer en behandeling van vasculaire risicofactoren

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 51, 2005, Pages 2844-2849

  De Leeuw, F E ^a   Van Norden, A G W ^a   Van Der Flier, W M ^b   Olde Rikkert, M G M ^a   Scheltens, Ph ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; STATIN;

ALZHEIMER DISEASE; ARTICLE; CHOLESTEROL DIET; COGNITIVE DEFECT; DIABETES MELLITUS; DISEASE COURSE; FOLLOW UP; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; RISK FACTOR;

ALZHEIMER DISEASE; DIABETES COMPLICATIONS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; RISK FACTORS;

EID: 29244448684     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet. 2001;357:169-75.
2. Vermeer SE, Prins ND, Heijer T den, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-22.
3. Zarow C, Vinters HV, Ellis WG, Weiner MW, Mungas D, White L, et al. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia. Ann Neurol. 2005;57:896-903.
4. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239-59.
5. Korf ESC, Scheltens Ph, Barkhof F, Leeuw F-E de. Blood pressure, white matter lesions and hippocampal atrophy: closing the gap between vascular pathology and Alzheimer's disease? Dement Geriatr Cogn Disord. 2005;20:331-7.
6. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Neurobiol Aging. 2000;21:57-62.
7. Leeuw FE de, Barkhof F, Scheltens Ph. White matter lesions and hippocampal atrophy in Alzheimer's disease. Neurology. 2004;62: 310-2.
8. Flier WM van der, Middelkoop HA, Weverling-Rijnsburger AW, Admiraal-Behloul F, Spilt A, Bollen EL, et al. Interaction of medial temporal lobe atrophy and white matter hyperintensities in AD. Neurology. 2004;62:1862-4.
9. Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med. 1994;154:2154-60.
10. Prince MJ, Bird AS, Blizard RA, Mann AH. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ. 1996;312:801-5.
11. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. PROGRESS Collaborative Group. Arch Intern Med. 2003;163:1069-75.
12. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. SCOPE Study Group. J Hypertens. 2003;21:875-86.
13. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-51.
14. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. PROSPER Study Group. Lancet. 2002; 360:1623-30.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360:7-22.
16. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002;52:346-50.
17. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005;62:753-7.
18. Pavlik VN, Hyman DJ, Doody R. Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III). Neuroepidemiology. 2005;24:42-50.
19. Ott A, Stolk RP, Harskamp F van, Pols HA, Hofman A, Breteler MMB. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology. 1999;53:1937-42.
20. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998;55:1449-55.
21. Ravaglia G, Forti P, Maioli F, Zanardi V, Dalmonte E, Grossi G, et al. Blood homocysteine and vitamin B levels are not associated with cognitive skills in healthy normally ageing subjects. J Nutr Health Aging. 2000;4:218-22.
22. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-83.
23. Seux ML, Forette F. Effects of hypertension and its treatment on mental function. Curr Hypertens Rep. 1999;1:232-7.
24. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141-5.
25. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21:49-55.
26. Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol. 1999;56:991-6.
27. Leeuw FE de, Barkhof F, Scheltens Ph. Alzheimer's disease - one clinical syndrome, two radiological expressions: a study on blood pressure. J Neurol Neurosurgery Psychiatry. 2004;75:1270-4.
28. Leeuw FE de, Barkhof F, Scheltens Ph. Progression of cerebral white matter lesions in Alzheimer's disease: a new window for therapy? J Neurol Neurosurg Psychiatry. 2005;76:1286-8.
29. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Systolic Hypertension in Europe Investigators. Arch Intern Med. 2002;162:2046-52.
30. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627-31.
31. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Cache County Study Investigators. Arch Gen Psychiatry. 2005;62:217-24.
32. ADVANCE Writing Committee. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation. J Hypertens. 2001;Suppl 4:S21-8.
33. Aisen PS, Egelko S, Andrews H, Diaz-Arrastia R, Weiner M, DeCarli C, et al. A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. Am J Geriatr Psychiatry. 2003;11:246-9.
34. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327:128.
35. Schmidt R, Scheltens P, Erkinjuntti T, Pantoni L, Markus HS, Wallin A, et al. White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. Neurology. 2004;63:139-44.